Advertisement
Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Optimal duration of anticoagulation

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH14-04-0396
Pages: -

Optimal duration of anticoagulation

Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests

Theme Issue Article for Theme Issue "Venous Thromboembolism"

P. Prandoni (1), S. Barbar (1), M. Milan (1), E. Campello (1), L. Spiezia (1), C. Piovella (1), R. Pesavento (1)

(1) Department of Medicine, Vascular Medicine Unit, University of Padua, Italy

Keywords

pulmonary embolism, Deep venous thrombosis, thrombophilia, venous thromboembolism, Ultrasonography, anticoagulation, residual thrombosis

Summary

Once anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years after a first episode is consistently around 30%. This risk is higher in patients with unprovoked than in those with (transient) provoked VTE, and among the latter in patients with medical than in those with surgical risk factors. Baseline parameters that have been found to be related to the risk of recurrent VTE are the proximal location of deep-vein thrombosis, obesity, old age, male sex and non-0 blood group, whereas the role of inherited thrombophilia is controversial. The persistence of residual vein thrombosis at ultrasound assessment has consistently been shown to increase the risk, as do persistently high values of D-dimer and the early development of the post-thrombotic syndrome. Although the latest international guidelines suggest indefinite anticoagulation for most patients with the first episode of unprovoked VTE, strategies that incorporate the assessment of residual vein thrombosis and D-dimer have the potential to identify subjects in whom anticoagulation can be safely discontinued. Moreover, new opportunities are offered by a few emerging anti-Xa and anti-IIa oral compounds, which are likely to induce fewer haemorrhagic complications than vitamin K antagonists while preserving the same effectiveness; and by low-dose aspirin, which has the potential to prevent the occurrence of both venous and arterial thrombotic events.

You may also be interested in...

1.
H. Leon Daneschvar1, Ali Seddighzadeh1, Gregory Piazza2, Samuel Z. Goldhaber1

Thromb Haemost 2008 99 6: 1035-1039

http://dx.doi.org/10.1160/TH08-02-0107

2.
Cihan Ay1,*, Lea V. Jungbauer2,*, Alexandra Kaider3, Silvia Koder1, Simon Panzer4, Ingrid Pabinger1, Christine Mannhalter2

Thromb Haemost 2008 99 5: 899-904

http://dx.doi.org/10.1160/TH07-11-0672

3.

Jurga Adomaityte, Maria Farooq, Rehan Qayyum

Thromb Haemost 2008 99 2: 338-342

http://dx.doi.org/10.1160/TH07-07-0468